Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
26 Feb, 26
ADA 2026 outlines the standards for obesity pharmacotherapy. It recommends combining person-centered medication with lifestyle changes for adults with obesity. It details weight-loss targets and drug benefits for comorbidities
23 Feb, 26
The updated international urticaria guideline describes its definition, classification and recommendations for diagnosing and managing its various subtypes.
4 Mar, 26
BMJ Open Res Clin.
- As per the analysis of 2016–2021 NIS data of adults with T1DM hospitalized for DKA, sex–age interactions influenced outcomes
- Women had lower AKI odds (aOR 0.56, 0.71, 0.79 across age groups) but higher sepsis odds (aOR 1.66, 1.31, 1.17; all p<0.05)
- Mortality benefit for women was limited to ages 18–44 (aOR 0.72)
- COVID-19 years saw mortality rise across all groups, most in young men (from 0.48% to 0.89%)
2 Mar, 26Eur Urol
- This randomized study showed that biparametric MRI‑first screening, regardless of PSA levels increased biopsy (10.8% vs 5.2%) and csPCa detection (4.6% vs 1.8%) as compared to those who received bpMRI only if PSA >3 ng/ml
- Benefit–harm metrics favored MRI first, with higher grade selectivity, biopsy efficiency, and biopsy avoidance
- The strategy was cost effective with no serious adverse events.
26 Feb, 26BMC Infect Dis.
- A recent meta-analysis showed that carbapenem-resistant Klebsiella pneumoniae had significantly higher resistance to penicillins (Risk Ratios, RR 2.74), cephalosporins (ceftazidime RR 2.71, cefepime RR 2.46, cefuroxime RR 3.06), and carbapenems (imipenem RR 5.52 and meropenem RR 5.33) vs. carbapenem-susceptible Klebsiella pneumoniae
- Results highlighted the need for strict surveillance and new therapies.
26 Feb, 26Diabetes Metab Syndr...
- In 789 Indian T2DM+MASLD patients (mean age 53.3 yrs), LSM ≥9.7 in 12.9%
- FIB 4 rule in cut off: 1.68 (AUROC 0.69, sens 64.7%, spec 65.2); NFS −0.389 (AUROC 0.619, sens 61.8%, spec 57.4)
- Rule out AUROCs poor (FIB 4 0.586, NFS 0.570), conventional cut offs had low sensitivity (~21%) but high specificity (~90%)
- Overall, FIB 4/NFS poorly predicted advanced fibrosis in Indian T2DM+MASLD patients.
The speaker highlighted Secukinumab’s expanding role in psoriasis care, emphasizing its strong data on clear-skin outcomes, sustained efficacy, favorable safety, and robust benefits in managing psoriatic comorbidities including PsA.
Featured
6 Mar, 26
4 Mar, 26
25 Feb, 26
